Latest Headlines

  1. Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit 8/21/2025

    Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category.

  2. PathAI And Moffitt Cancer Center Announce Strategic Collaboration To Deploy The AISight Dx Digital Pathology Platform And Advance AI Diagnostics 8/21/2025

    PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation’s top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI’s digital pathology platform, AISight Dx, across Moffitt’s pathology programs to transform cancer detection and innovation.

  3. ISS National Lab-Sponsored Experiment Tests 3D Bioprinted Tissue For Growing Artificial Livers 8/20/2025

    To explore how 3D bioprinted liver tissue constructs complete with vascular channels behave in microgravity, the Wake Forest Institute for Regenerative Medicine (WFIRM) is sending an investigation to the International Space Station (ISS).

  4. Agilent MMR IHC Panel pharmDx (Dako Omnis) Receives FDA Approval As A Companion Diagnostic Test For Colorectal Cancer 8/20/2025

    Agilent Technologies Inc. today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer.

  5. LabConnect Launches LabConnector™ To Streamline Lab Data Integration 8/19/2025

    LabConnect, LLC, a global leader in central laboratory services for clinical trials, today announced the launch of LabConnector™, a powerful new technology solution that transforms the way laboratory data is exchanged and managed for clinical trials.

  6. Ultima Genomics And Gene By Gene Partner To Expand Global Access To High-Quality, Low-Cost Sequencing On The UG 100™ Platform 8/19/2025

    Ultima Genomics, Inc., developer of the UG 100™ next-generation sequencing (NGS) platform, and Gene by Gene, a leading global provider of advanced genetic testing and genomic services, today announced a partnership to broaden worldwide access to high-quality, cost-effective DNA sequencing.

  7. Biolabs International's New App Cuts Clinic Visits, Expands Testing Access 8/19/2025

    Biolabs International LLC, a healthcare innovation company based in San Diego, California, is transforming how diagnostics are delivered and accessed , both in the home and in clinical research.

  8. Twist Bioscience Launches Oncology DNA CGP Panel To Advance Precision Medicine With Customizable, Platform-Agnostic NGS Solution 8/19/2025

    Twist Bioscience Corporation, a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic Profiling (CGP) Panel, a customizable, research-use-only solution designed to empower users to identify genomic alterations for a broad set of tumors, guide targeted therapy development and support clinical and translational oncology research.

  9. Biodesix Recognized As A Thermo Fisher Scientific Center Of Excellence (COE) For NGS Diagnostics 8/19/2025

    Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher’s collaborative initiative to advance NGS-based diagnostics.

  10. Labcorp Launches First FDA-Cleared Blood Test For Alzheimer's Disease 8/18/2025

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection of the amyloid plaques associated with the disease in appropriate patients.